Antibody-producing cells discovered in spleen

Image
Press Trust of India London
Last Updated : Feb 24 2014 | 5:02 PM IST
Researchers have discovered a type of cells in human spleen that are essential for the production of antibodies, paving way for development of new vaccines to fight meningitis and pneumonia.
Innate lymphoid cells were recently described by the scientific community and represent the first line of immunological defence on our body surfaces, which are constantly exposed to bacteria, such as the intestine or skin.
Now, for the first time their presence and function in human spleen has been described, said Dr Giuliana Magri, member of the research group of B Cell Biology at IMIM (Institut Hospital del Mar d'Investigacions Mediques) in Barcelona, and first author in the paper.
"We have discovered how these cells regulate the innate immune response of a subset of splenic B lymphocytes that are responsible to fight against encapsulated bacteria, causative agents of meningitis or pneumonia," said Magri.
"The current available vaccines against encapsulated bacteria confer only a limited protection in immunodeficient patients, and are too expensive to be implemented in developing countries.
"At the same time, we lack information on the underlying mechanisms that regulate B lymphocytes, which has been a major hurdle in the development of novel vaccine strategies," said Dr Andrea Cerutti, ICREA (Institucio Catalana de Recerca i Estudis Avancats) research professor and leader in the field of B lymphocyte biology.
"This makes the current discovery key in the design of novel more efficient and well-oriented therapies," Cerutti said.
The research involved in vitro studies with isolated cells from human spleen samples and in vivo studies performed with different mice models.
The work explored the function of the innate lymphoid cells in homeostasis, in short, in the absence of any illness, opening the door in the future to study the possible implication of innate lymphoid cells in diverse pathological processes both at the mucosal and systemic level, as well as deepening the understanding of autoimmune and immunodeficient diseases.
The study was published in the journal Nature Immunology.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 24 2014 | 5:02 PM IST

Next Story